Patheon Acquires Roche API Manufacturing Site in S.C.

Pharmaceutical manufacturing and development company Patheon announced Monday that it has signed an agreement with Roche Holdings Ltd. to acquire an active pharmaceutical ingredients (API) manufacturing site in Florence, SC.

“As the only end-to-end provider of pharma development and manufacturing services, Patheon is uniquely positioned to integrate this new site into our global network and quickly leverage the capabilities with existing and new clients,” said James Mullen, chief executive officer of Patheon in a press release. “The company will benefit from the additional North American API capacity and adds a state-of-the-art facility with approximately 200 scientific and manufacturing professionals.”

Patheon’s press release said the company is purchasing the site for a “immaterial sum” and an added cost of associated inventory and spare parts. A multi-year supply arrangement was entered between Patheon and Roche, which Patheon said should cover the costs of operating the facility over the next few years as it ramps up client work there.

The 300,000-sq-ft facility sits on 1100 acres in Florence, and has a manufacturing capacity for API that extends from development to manufacturing services, the company said. Beyond the acquisition of the existing facilities, Patheon said it will expand capacity for highly potent compounds there and provide additional capabilities to support solid-state chemistry, micronization, and commercial spray drying.

Reactors at the site range from 50 to 11,000 liters and can produce a variety of products simultaneously. Products from clinical to commercial scale can be produced there, according to Patheon.

Click here for information about the Powder & Bulk Solids Montreal Showcase

For related articles, news, and equipment reviews, visit our Equipment Zones